GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $4,451,206.62 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,551 shares of the stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $95.62, for a total value of $4,451,206.62. Following the completion of the transaction, the chief executive officer now directly owns 48,314 shares of the company’s stock, valued at approximately $4,619,784.68. The trade was a 49.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total transaction of $96,416.32.
• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total transaction of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total transaction of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Stock Down 2.3 %

Shares of GeneDx stock opened at $92.20 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 12-month low of $8.53 and a 12-month high of $115.60. The firm has a market capitalization of $2.59 billion, a PE ratio of -47.04 and a beta of 1.91. The stock’s fifty day moving average is $87.28 and its 200-day moving average is $73.92.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. Equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. William Blair Investment Management LLC acquired a new stake in GeneDx during the 4th quarter valued at $51,496,000. Lord Abbett & CO. LLC acquired a new position in GeneDx during the fourth quarter valued at $48,458,000. Summit Partners Public Asset Management LLC lifted its stake in GeneDx by 336.9% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock worth $58,073,000 after acquiring an additional 582,619 shares in the last quarter. Science & Technology Partners L.P. acquired a new stake in GeneDx during the 4th quarter worth about $30,821,000. Finally, Fred Alger Management LLC purchased a new position in GeneDx during the 3rd quarter valued at about $16,731,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on WGS. The Goldman Sachs Group lifted their target price on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.